atezolizumab + bevacizumab + paclitaxel

The drug combination "atezolizumab + bevacizumab + paclitaxel" is a therapeutic regimen used primarily in oncology, specifically for the treatment of non-small cell lung cancer (NSCLC). This combination brings together an immune checkpoint inhibitor, an anti-angiogenic agent, and a chemotherapy drug to create a multi-modal approach to cancer treatment.\n\nThis combination therapy works through multiple mechanisms:\n\n1. **Atezolizumab (Tecentriq)** is a PD-L1 inhibitor that helps restore anti-tumor T-cell activity by preventing the cancer cells from evading immune detection[6].\n\n2. **Bevacizumab (Avastin)** is an anti-angiogenic agent that targets vascular endothelial growth factor (VEGF) to inhibit the formation of new blood vessels that supply tumors[5][7].\n\n3. **Paclitaxel** is a chemotherapy drug that disrupts microtubule function, which is essential for cell division, thereby preventing cancer cells from proliferating[5].\n\nThis combination represents an important advancement in the treatment of metastatic NSCLC, offering patients a multi-targeted approach that addresses different aspects of cancer biology.

Brand names

AvastinTecentriq

Other names

paclitaxel + bevacizumab + atezolizumab